The North American drug delivery technologies market is highly competitive, and is marked with the presence of several big and emerging players. Prominent players in this market include Johnson & Johnson Services, Inc. (U.S.), Novartis AG (Switzerland), F. Hoffman-La Roche Ltd. (Switzerland), Bayer AG (Germany), Pfizer, Inc. (U.S.), 3M Company (U.S.), Becton, Dickinson and Company (U.S.), Merck & Co, Inc. (U.S.), Sanofi (France), and Antares Pharma, Inc. (U.S.). Some of the other players in this market include Eli Lilly and Company (U.S.), Baxter International, Inc. (U.S.), Skye Pharma (France), Gerresheimer (Germany), West Pharmaceutical Services, Inc. (U.S.), Schott AG (Germany), CIMA Labs (U.S.), Catalent Pharma Solutions (U.S.), Aptalis Pharma, Inc. (U.S.), Endo Health Solutions (U.S.), Nektar Therapeutics, Inc. (U.S.), OptiNose AS (Norway), Psivida Corporation (U.S.), EyeGate Pharmaceutical (U.S.), and Galderma, Inc. (U.S.).
Companies operating in this market are focusing on organic as well as inorganic growth strategies, such as new product launches and product approvals; agreements, partnerships, and collaborations; expansions; and acquisitions. New product launches and product approvals accounted for the largest share of the overall growth strategies adopted by market players between 2013 and 2016. Various new and technologically advanced products were launched in the market during this period. For instance, in April 2016, 3M Drug Delivery Systems (U.S.) launched the Intelligent Control Inhaler for patients suffering from respiratory diseases. This inhaler delivers accurate medication doses to patients and provides on-screen instructions for use and feedback to patients and healthcare providers through an app. Also, in February 2016, Jonson & Johnson, Inc. (U.S.) launched the RHINOCORT Allergy Spray. In recent years, prominent players in this market received approvals to market their products in North America. Some of the recently approved products include CyPass Micro-Stent, a micro invasive glaucoma surgical (MIGS) device (Novartis AG, August 2016); Tecentriq (atezolizumab) (Hoffman-La-Roche Ltd, May 2016); and XELJANZ XR (tofacitinib citrate) extended-release 11 mg tablets (Pfizer, Inc., February 2016).
Key players that had a major focus on new product launches and product approvals include Johnson & Johnson Inc. (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (U.S.), Antares Pharma, Inc. (U.S.), Bayer AG (Germany), Becton, Dickinson and Company (U.S.), GlaxoSmithKline plc (U.K.), 3M Company (U.S.), Merck & Co., Inc. (U.S.), and Sanofi (France).
